Extensive fibromatosis, also called desmoid tumor, is a histologically benign tumor, which is nonetheless serious due to its recurrent character and to its potential for infiltration of neighboring tissues. Extensive surgery is the only effective means of treatment, radiation therapy being used only as a complement. The authors describe an elective location of the lesion in the sheaths of the scalenus muscles. This development is usually observed in young women, as is the case in the observation reported here.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Superficial acral fibromyxoma on the palm: a case report.
J Med Case Rep
January 2025
Department of Clinical Medicine, Jining Medical University, Jining, China.
Background: Superficial acral fibromyxoma is a noncancerous, benign tumor of soft tissue with an unidentified origin. Occurrences of abnormalities on the palm are less frequently documented.
Case Report Presentation: A 47-year-old East Asian woman presented with a palm tumor on her left knuckle that had been present for 4 months.
Chondrosarcoma proximal tibia secondary to chondromyxoid fibroma: A rare case report.
Int J Surg Case Rep
January 2025
Department of Orthopaedics, All India Institute of Medical Sciences (AIIMS), Marudhar Industrial Area, 2nd phase, M.I.A. 1st phase, Basni, Jodhpur, Rajasthan 342005, India.
Introduction: Benign cartilage tumours with malignant transformation are reported very few. Aiming to report a secondary chondrosarcoma in proximal tibia after chondromyxoid fibroma: a rare entity with limited experience of management.
Case Presentation: we present a challenging case of secondary chondrosarcoma of proximal tibia in surgically managed chondromyxoid fibroma.
Anti-tumor Effects of Idarubicin Hydrochloride in Desmoid Tumors.
Anticancer Res
December 2024
Drug Discovery Platform Research Center, Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Republic of Korea;
Background/aim: Desmoid tumors (DTs), also referred to as aggressive fibromatosis, originate from connective tissues and typically manifest with a propensity for local invasion. Despite extensive research efforts aimed at exploring novel anti-tumor agents for DTs, the development of effective clinical management strategies remains an ongoing challenge due to the limited success of current treatments, which frequently lead to inconsistent outcomes and a high recurrence rate of DTs. To overcome these limitations, we focused our research aim on a drug repositioning approach to identify existing medications that could be effective against DTs.
View Article and Find Full Text PDFComplex Surgical Management of Extensive Chest-Wall Desmoid Fibromatosis.
Cureus
October 2024
General Surgery, George Washington University, Washington, DC, USA.
Desmoid fibromatosis (DF) is a rare tumor that arises from fibroblasts and myofibroblasts and typically presents on the trunk and limbs. While metastasis of fibromatosis is exceedingly uncommon, DF can spread rapidly to adjacent tissue. Its aggressive nature and frequent recurrence pose challenges for treatment, often requiring a multidisciplinary approach.
View Article and Find Full Text PDFChronic hearing loss turns out being a calcified chondroid mesenchymal neoplasm with FN1::FGFR2 fusion.
Eur Arch Otorhinolaryngol
October 2024
Barmherzige Brüder Klinikum St. Elisabeth Straubing, Klinik für Hals-Nasen-Ohren-Heilkunde mit Kopf-Hals- und plastischer Gesichtschirurgie, Straubing, Germany.
Article Synopsis
- * The tumor, identified as a "calcified chondroid mesenchymal neoplasm" (CCMN) through molecular analysis, was surgically removed, showing extensive changes indicative of its aggressive nature.
- * Follow-up imaging for over two years showed no residual tumor, but ongoing monitoring is crucial due to potential local recurrences; targeted therapies may be considered for any future recurrences involving the FGFR2 fusion.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!